Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ferdinandos Skoulidis, Kathryn Cecilia Arbour, Matthew David Hellmann, Pradnya Dinkar Patil, Melina Elpi Marmarelis, Mark M. Awad, Joseph Christopher Murray, Jessica Hellyer, Justin F. Gainor, Anastasios Dimou, Christine M. Bestvina, Catherine A. Shu, Jonathan W. Riess, Collin Michael Blakely, Chad Victor Pecot, Laura Mezquita, Fabrizio Tabbò, Matthias Scheffler, Vassiliki Papadimitrakopoulou, John Heymach
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, Brigham and Women's Hospital, Massachusetts General Hospital, Johns Hopkins University, Johns Hopkins Medicine, Stanford Cancer Institute, University of Colorado Cancer Center, University of Chicago, Columbia University Irving Medical Center, UC Davis Comprehensive Cancer Center, University of California, San Francisco, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, University of Turin, University of Cologne, University Hospital Cologne
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947248753